Search

Your search keyword '"Guadagnolo, B. Ashleigh"' showing total 432 results
Start Over Author "Guadagnolo, B. Ashleigh"
432 results on '"Guadagnolo, B. Ashleigh"'

2. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

Author

Roland, Christina L., Nassif Haddad, Elise F., Keung, Emily Z., Wang, Wei-Lien, Lazar, Alexander J., Lin, Heather, Chelvanambi, Manoj, Parra, Edwin R., Wani, Khalida, Guadagnolo, B. Ashleigh, Bishop, Andrew J., Burton, Elizabeth M., Hunt, Kelly K., Torres, Keila E., Feig, Barry W., Scally, Christopher P., Lewis, Valerae O., Bird, Justin E., Ratan, Ravin, Araujo, Dejka, Zarzour, M. Alexandra, Patel, Shreyaskumar, Benjamin, Robert, Conley, Anthony P., Livingston, J. Andrew, Ravi, Vinod, Tawbi, Hussein A., Lin, Patrick P., Moon, Bryan S., Satcher, Robert L., Mujtaba, Bilal, Witt, Russell G., Traweek, Raymond S., Cope, Brandon, Lazcano, Rossana, Wu, Chia-Chin, Zhou, Xiao, Mohammad, Mohammad M., Chu, Randy A., Zhang, Jianhua, Damania, Ashish, Sahasrabhojane, Pranoti, Tate, Taylor, Callahan, Kate, Nguyen, Sa, Ingram, Davis, Morey, Rohini, Crosby, Shadarra, Mathew, Grace, Duncan, Sheila, Lima, Cibelle F., Blay, Jean-Yves, Fridman, Wolf Herman, Shaw, Kenna, Wistuba, Ignacio, Futreal, Andrew, Ajami, Nadim, Wargo, Jennifer A., and Somaiah, Neeta

Published
2024
Full Text
View/download PDF

10. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development

Author

Thomson, David J, Yom, Sue S, Saeed, Hina, El Naqa, Issam, Ballas, Leslie, Bentzen, Soren M, Chao, Samuel T, Choudhury, Ananya, Coles, Charlotte E, Dover, Laura, Guadagnolo, B Ashleigh, Guckenberger, Matthias, Hoskin, Peter, Jabbour, Salma K, Katz, Matthew S, Mukherjee, Somnath, Rembielak, Agata, Sebag-Montefiore, David, Sher, David J, Terezakis, Stephanie A, Thomas, Toms V, Vogel, Jennifer, and Estes, Christopher

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Mind and Body, Clinical Research, Good Health and Well Being, COVID-19, Coronavirus Infections, Dose Fractionation, Radiation, Evidence-Based Medicine, Humans, Pandemics, Pneumonia, Viral, Publications, Other Physical Sciences, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeNumerous publications during the COVID-19 pandemic recommended the use of hypofractionated radiation therapy. This project assessed aggregate changes in the quality of the evidence supporting these schedules to establish a comprehensive evidence base for future reference and highlight aspects for future study.Methods and materialsBased on a systematic review of published recommendations related to dose fractionation during the COVID-19 pandemic, 20 expert panelists assigned to 14 disease groups named and graded the highest quality of evidence schedule(s) used routinely for each condition and also graded all COVID-era recommended schedules. The American Society for Radiation Oncology quality of evidence criteria were used to rank the schedules. Process-related statistics and changes in distributions of quality ratings of the highest-rated versus recommended COVID-19 era schedules were described by disease groups and for specific clinical scenarios.ResultsFrom January to May 2020 there were 54 relevant publications, including 233 recommended COVID-19-adapted dose fractionations. For site-specific curative and site-specific palliative schedules, there was a significant shift from established higher-quality evidence to lower-quality evidence and expert opinions for the recommended schedules (P = .022 and P < .001, respectively). For curative-intent schedules, the distribution of quality scores was essentially reversed (highest levels of evidence "pre-COVID" vs "in-COVID": high quality, 51.4% vs 4.8%; expert opinion, 5.6% vs 49.3%), although there was variation in the magnitude of shifts between disease sites and among specific indications.ConclusionsA large number of publications recommended hypofractionated radiation therapy schedules across numerous major disease sites during the COVID-19 pandemic, which were supported by a lower quality of evidence than the highest-quality routinely used dose fractionation schedules. This work provides an evidence-based assessment of these potentially practice-changing recommendations and informs individualized decision-making and counseling of patients. These data could also be used to support radiation therapy practices in the event of second waves or surges of the pandemic in new regions of the world.

Published
2020

11. The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcoma

Author

Heng, Marilyn, Gupta, Abha, Chung, Peter W, Healey, John H, Vaynrub, Max, Rose, Peter S, Houdek, Matthew T, Lin, Patrick P, Bishop, Andrew J, Hornicek, Francis J, Chen, Yen-Lin, Lozano-Calderon, Santiago, Holt, Ginger E, Han, Ilkyu, Biau, David, Niu, Xiaohui, Bernthal, Nicholas M, Ferguson, Peter C, Wunder, Jay S, Group, Japanese Musculoskeletal Oncology, Ueda, Takafumi, Kakunaga, Shigeki, Kawai, Akira, Sugiura, Hideshi, Kidani, Teruki, Kunisasa, Toshiyuki, Ozaki, Toshifumi, Ae, Keisuke, Nagano, Akihito, Ohno, Takatoshi, Hiraoka, Koji, Yamamoto, Norio, Tsuchiya, Hiroyuki, Matsumoto, Yoshihiro, Yanagawa, Takashi, Nakayama, Robart, Morioka, Hideo, Kubo, Tadahiko, Simose, Shoji, Yamagami, Yoshiki, Yamamoto, Tetsuji, Kawasaki, Motohiro, Torigoe, Tomoaki, Yazawa, Yasuo, Akiyama, Toru, Gokita, Tabu, Manabe, Jun, Kaya, Mitsunori, Emori, Makoto, Nakamura, Tomoki, Matsumine, Akihiko, Sugihara, Shinsuke, Yokouchi, Masahiro, Komiya, Setsuro, Suehara, Yoshiyuki, Takagi, Tatsuya, Kawamoto, Teruya, Wasa, Junji, Yonemoto, Tsukasa, Ishii, Takeshi, Baba, Ichiro, Hoshi, Manabu, Hamada, Kenichiro, Naka, Norifumi, Sotobori, Tsukasa, Araki, Nobuhito, Okuma, Tomotake, Goto, Takahiro, Kobayashi, Hiroshi, Kawano, Hirotaka, Hosaka, Masami, Futani, Hiroyuki, Hiraga, Hiroaski, Nishida, Yoshihiro, Collaborative, Soft Tissue Osteosarcoma International, Griffin, Anthony, Razak, Albiruni R Abdul, Shultz, David Benjamin, Catton, Charles, Robinson, Steven, Patel, Shreyaskumar R, Lewis, Valerae O, Guadagnolo, B Ashleigh, DeLaney, Thomas, Wang, Haotong, Raskin, Kevin, Callan, Alexandra K, Henshaw, Robert, Isler, Marc, Mottard, Sophie, Chen, Wei-Ming, Traub, Frank, Chen, Tom Wei-Wu, Turcotte, Robert E, Davidson, Darin, Tunn, Per-Ulf, Loong, Herbert, Ghert, Michelle, Werier, Joel, and Clarkson, Paul

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, Clinical Research, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Osteosarcoma, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Young Adult, Extraskeletal osteosarcoma, Soft-tissue osteosarcoma, Chemotherapy, Radiotherapy, Radiation therapy, Japanese Musculoskeletal Oncology Group, Soft Tissue Osteosarcoma International Collaborative, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe role of chemotherapy (CT) and radiotherapy (RT) for management of extraskeletal osteosarcoma (ESOS) remains controversial. We examined disease outcomes for ESOS patients and investigated the association between CT/RT with recurrence and survival.Patients and methodsRetrospective review at 25 international sarcoma centers identified patients ≥18 years old treated for ESOS from 1971 to 2016. Patient/tumour characteristics, treatment, local/systemic recurrence, and survival data were collected. Kaplan-Meier survival and Cox proportional-hazards regression and cumulative incidence competing risks analysis were performed.Results370 patients with localized ESOS treated definitively with surgery presented with mainly deep tumours (n = 294, 80%). 122 patients underwent surgical resection alone, 96 (26%) also received CT, 70 (19%) RT and 82 (22%) both adjuvants. Five-year survival for patients with localized ESOS was 56% (95% CI 51%-62%). Almost half of patients (n = 173, 47%) developed recurrence: local 9% (35/370), distant 28% (102/370) or both 10% (36/370). Considering death as a competing event, there was no significant difference in cumulative incidence of local or systemic recurrence between patients who received CT, RT, both or neither (local p = 0.50, systemic p = 0.69). Multiple regression Cox analysis showed a significant association between RT and decreased local recurrence (HR 0.46 [95% CI 0.26-0.80], p = 0.01).ConclusionAlthough the use of RT significantly decreased local recurrences, CT did not decrease the risk of systemic recurrence, and neither CT, nor RT nor both were associated with improved survival in patients with localized ESOS. Our results do not support the use of CT; however, adjuvant RT demonstrates benefit in patients with locally resectable ESOS.

Published
2020

12. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial

Author

Guadagnolo, B Ashleigh, Bassett, Roland L, Mitra, Devarati, Farooqi, Ahsan, Hempel, Caroline, Dorber, Courtney, Willis, Tiara, Wang, Wei-Lien, Ratan, Ravin, Somaiah, Neeta, Benjamin, Robert S, Torres, Keila E, Hunt, Kelly K, Scally, Christopher P, Keung, Emily Z, Satcher, Robert L, Bird, Justin E, Lin, Patrick P, Moon, Bryan S, Lewis, Valerae O, Roland, Christina L, and Bishop, Andrew J

Published
2022
Full Text
View/download PDF

17. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort.

Author

Nakazawa, Michael S, Livingston, J Andrew, Zarzour, Maria A, Bishop, Andrew J, Ratan, Ravin, Ludwig, Joseph A, Araujo, Dejka M, Somaiah, Neeta, Ravi, Vinod, Nassif, Elise F, Roland, Christina L, Lazar, Alexander J, Guadagnolo, B Ashleigh, Harrison, Douglas J, Benjamin, Robert S, Patel, Shreyaskumar R, and Conley, Anthony P

Subjects
TREATMENT effectiveness, CANCER chemotherapy, SARCOMA, COMBINED modality therapy, OVERALL survival
Abstract

Background: Rhabdomyosarcomas are the most common soft tissue sarcoma in children, and pediatric alveolar rhabdomyosarcoma (ARMS) prognosis has improved based on cooperative studies. However, in adults, ARMS is significantly rarer, has poorer outcomes, and currently lacks optimal treatment strategies. Objective: This study aimed to evaluate the clinical outcome of an adult ARMS population with different front-line systemic chemotherapies and determine if any chemotherapy regimen is associated with improved survival. Materials and methods: This is a retrospective study of histologically confirmed fusion-positive ARMS patients over 18 years of age, who were treated at MD Anderson Cancer Center (MDACC) from 2004 to 2021 and received systemic chemotherapy. Descriptive clinical statistics were performed, including staging, front-line chemotherapy, multimodal therapy usage, response rates, and survival analyses. Results: 49 ARMS patients who received upfront chemotherapy were identified. Locoregional treatments included radiotherapy (RT) alone (29%, n = 14), surgery alone (10%, n = 5), or both (45%, n = 22). Median overall survival (OS) for the entire cohort was 3.6 years, and the overall response rate to systemic therapy was 89%. No chemotherapy regimen showed OS benefit, specifically analyzing the pediatric-based vincristine, actinomycin-D, cyclophosphamide (VAC) or adult-based vincristine, doxorubicin, ifosfamide (VDI) regimens, even when controlled for other clinical risk factors. Conclusion: In this single-center contemporary series, adult ARMS patient outcomes remain poor. There was no statistically significant OS difference in patients who did or did not receive adult or pediatric based ARMS regimens, although a high overall response rate to chemotherapy was seen across the entire cohort. Based on these observations, further randomized prospective studies are necessary to delineate which frontline chemotherapy regimen is most beneficial in this rare adult cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. What Is a Sarcoma 'Specialist Center'? Multidisciplinary Research Finds an Answer.

Author

Wilson, Roger, Reinke, Denise, van Oortmerssen, Gerard, Gonzato, Ornella, Ott, Gabriele, Raut, Chandrajit P., Guadagnolo, B. Ashleigh, Haas, Rick L. M., Trent, Jonathan, Jones, Robin, Pretorius, Lauren, Felser, Brandi, Basson, Mandy, Schuster, Kathrin, and Kasper, Bernd

Subjects
CANCER treatment, SARCOMA, MEDICAL specialties & specialists, MEDICAL quality control, MEDICAL care, PATIENT advocacy, BUSINESS networks, INTERDISCIPLINARY research, QUALITY assurance, SPECIALTY hospitals, HEALTH care teams
Abstract

Simple Summary: A multidisciplinary group researched and defined criteria to describe a sarcoma specialist treatment center or network. The project is led by Sarcoma Patient Advocacy Global Network (SPAGN), involves patient groups from around the world and is supported by clinical specialists and leading researchers. The paper identifies Core Principles and Key Features which define a specialist center/network. They are supported by evidence and experience. A primary aim is that new patients and their families can identify a specialist center which can provide curative treatment. A secondary aim is that countries where specialist treatment is not yet available can identify what they have to achieve to meet that ambition. The Core Principles allow a center or network to attain accreditation as a Sarcoma Intelligent Specialist Network. The Key Features are more aspirational and are expressed in a way that allows local needs, legal considerations and budgetary pressures to be taken into account. This is the first time an expert multidisciplinary group has defined specialism in cancer treatment in a worldwide context. The management of sarcomas in specialist centers delivers significant benefits. In much of the world, specialists are not available, and the development of expertise is identified as a major need. However, the terms 'specialist' or 'expert' center are rarely defined. Our objective is to offer a definition for patient advocates and a tool for healthcare providers to underpin improving the care of people with sarcoma. SPAGN developed a discussion paper for a workshop at the SPAGN 2023 Conference, attended by 75 delegates. A presentation to the Connective Tissue Oncology Society (CTOS) and further discussion led to this paper. Core Principles were identified that underlie specialist sarcoma care. The primary Principle is the multi-disciplinary team discussing every patient, at first diagnosis and during treatment. Principles for optimal sarcoma management include accurate diagnosis followed by safe, high-quality treatment, with curative intent. These Principles are supplemented by Features describing areas of healthcare, professional involvement, and service provision and identifying further research and development needs. These allow for variations because of national or local policies and budgets. We propose the term 'Sarcoma Intelligent Specialist Network' to recognize expertise wherever it is found in the world. This provides a base for further discussion and local refinement. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy.

Author

Yoder, Alison K, Farooqi, Ahsan S, Wernz, Cort, Subramaniam, Aparna, Ravi, Vinod, Goepfert, Ryan, Sturgis, Erich M, Mitra, Devarati, Bishop, Andrew J, and Guadagnolo, B Ashleigh

Subjects
RADIOTHERAPY, PROPORTIONAL hazards models, SCALP
Abstract

Introduction: We investigated outcomes and prognostic factors for patients treated for cutaneous angiosarcoma (CA). Methods: We conducted a retrospective review of patients treated for CA of the face and scalp from 1962 to 2019. All received definitive treatment with surgery, radiation (RT), or a combination (S‐XRT). The Kaplan–Meier method was used to estimate outcomes. Multivariable analyses were conducted using the Cox proportional hazards model. Results: For the 143 patients evaluated median follow‐up was 33 months. Five‐year LC was 51% and worse in patients with tumors >5 cm, multifocal tumors, those treated pre‐2000, and with single modality therapy (SMT). These remained associated with worse LC on multivariable analysis. The 5‐year disease‐specific survival (DSS) for the cohort was 56%. Tumor size >5 cm, non‐scalp primary site, treatment pre‐2000, and SMT were associated with worse DSS. Conclusion: Large or multifocal tumors are negative prognostic factors in patients with head and neck CA. S‐XRT improved outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression

Author

Mitra, Devarati, primary, Farr, Morgan, additional, Nagarajan, Priyadharsini, additional, Ho, Joel, additional, Bishop, Andrew J., additional, Jhingran, Anuja, additional, Farooqi, Ahsan S., additional, Frumovitz, Michael, additional, Amaria, Rodabe N., additional, McQuade, Jennifer L., additional, Jazaeri, Amir A., additional, and Guadagnolo, B. Ashleigh, additional

Published
2022
Full Text
View/download PDF

43. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

Author

Ho, Joel, primary, Mattei, Jane, additional, Tetzlaff, Michael, additional, Williams, Michelle D., additional, Davies, Michael A., additional, Diab, Adi, additional, Oliva, Isabella C. Glitza, additional, McQuade, Jennifer, additional, Patel, Sapna P., additional, Tawbi, Hussein, additional, Wong, Michael K., additional, Fisher, Sarah B., additional, Hanna, Ehab, additional, Keung, Emily Z., additional, Ross, Merrick, additional, Weiser, Roi, additional, Su, Shirley Y., additional, Frumovitz, Michael, additional, Meyer, Larissa A., additional, Jazaeri, Amir, additional, Pettaway, Curtis A., additional, Guadagnolo, B. Ashleigh, additional, Bishop, Andrew J., additional, Mitra, Devarati, additional, Farooqi, Ahsan, additional, Bassett, Roland, additional, Faria, Silvana, additional, Nagarajan, Priyadharsini, additional, and Amaria, Rodabe N., additional

Published
2022
Full Text
View/download PDF

44. ASO Visual Abstract: Re-Excision After Unplanned Excision of Soft Tissue Sarcoma Is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease

Author

Traweek, Raymond S., primary, Martin, Allison N., additional, Rajkot, Nikita F., additional, Guadagnolo, B. Ashleigh, additional, Bishop, Andrew J., additional, Lazar, Alexander J., additional, Keung, Emily Z., additional, Torres, Keila E., additional, Hunt, Kelly K., additional, Feig, Barry W., additional, Roland, Christina L., additional, and Scally, Christopher P., additional

Published
2022
Full Text
View/download PDF

47. ASO Visual Abstract: Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma

Author

Erstad, Derek J., primary, Chiang, Yi-Ju, additional, Witt, Russell G., additional, Cope, Brandon, additional, Nassif, Elise F., additional, Scally, Christopher P., additional, Torres, Keila E., additional, Feig, Barry W., additional, Hunt, Kelly K., additional, Bishop, Andrew J., additional, Guadagnolo, B. Ashleigh, additional, Roland, Christina L., additional, and Keung, Emily Z., additional

Published
2022
Full Text
View/download PDF

48. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma

Author

Erstad, Derek J., primary, Chiang, Yi-Ju, additional, Witt, Russell G., additional, Cope, Brandon, additional, Nassif, Elise F., additional, Scally, Christopher P., additional, Torres, Keila E., additional, Feig, Barry W., additional, Hunt, Kelly K., additional, Bishop, Andrew J., additional, Guadagnolo, B. Ashleigh, additional, Roland, Christina L., additional, and Keung, Emily Z., additional

Published
2022
Full Text
View/download PDF

49. Re-excision After Unplanned Excision of Soft Tissue Sarcoma is Associated with High Morbidity and Limited Pathologic Identification of Residual Disease

Author

Traweek, Raymond S., primary, Martin, Allison N., additional, Rajkot, Nikita F., additional, Guadagnolo, B. Ashleigh, additional, Bishop, Andrew J., additional, Lazar, Alexander J., additional, Keung, Emily Z., additional, Torres, Keila E., additional, Hunt, Kelly K., additional, Feig, Barry W., additional, Roland, Christina L., additional, and Scally, Christopher P., additional

Published
2022
Full Text
View/download PDF

50. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma

Author

Bishop, Andrew J., primary, Amini, Behrang, additional, Lin, Heather, additional, Raza, Shaan M., additional, Patel, Shreyaskumar, additional, Grosshans, David R., additional, Ghia, Amol, additional, Farooqi, Ahsan, additional, Guadagnolo, B. Ashleigh, additional, Mitra, Devarati, additional, Akdemir, Kadir C., additional, Lazar, Alexander J., additional, Wang, Wei-Lien, additional, Alvarez-Breckenridge, Christopher, additional, Bird, Justin, additional, Rhines, Laurence D., additional, Somaiah, Neeta, additional, and Conley, Anthony P., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results